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Visual impairment is a world-wide health problem affecting about 285 million people [1]. 
Recently, it was estimated that with aging populations in high-income regions of 
Central/Eastern Europe glaucoma and diabetic retinopathy will become the most important 
causes of vision loss [2]. Glaucoma is one of the major ocular neurodegenerative diseases 
leading to loss of visual function and impaired quality of life [3]. Elevated intraocular 
pressure (IOP) is considered the main risk factor, and although it is no longer used to 
diagnose the disease, IOP is still the only target for glaucoma therapy [4]. Pharmacological 
therapies aiming at lowering IOP, including drugs that increase aqueous humor outflow or 
suppress aqueous humor production, are currently available [5]. However, lowering IOP 
does not always prevent the progression of the disease. Optic atrophy can occur in the 
presence of IOP values that fall within the normal range (i.e., normal tension glaucoma), 
and clinical studies have documented that even when IOP is pharmacologically controlled, 
optic nerve damage can still progress in a significant number of patients [6-7]. Apoptotic 
retinal ganglion cell (RGC) death is the final event leading to visual loss in glaucoma [8], 
and therefore, strategies aimed at preventing or attenuating RGC degeneration might fulfill 
the need for a better glaucoma treatment. Efforts have been made to identify drugs 
endowed with neuroprotective effects and able to preserve visual functioning. However, the 
recent unexpected failure of a clinical trial on patients with glaucoma testing the efficacy of 
memantine, an uncompetitive N-methyl D-aspartate (NMDA) receptor antagonist 




neuroprotection in glaucoma [9]. Diabetic retinopathy is a major complication in diabetic 
patients and can lead to blindness. Diabetic retinopathy is a microvascular complication and 
is currently being viewed as a neurovascular complication in light of several recent reports 
[10-11. Some of these reports suggest that changes in neuronal components occur soon 
after the onset of diabetes and precedes vascular complications associated with diabetic 
retinopathy. A recent study has indicated retinal neuronal dysfunction to occur as early as 2 
days after onset of experimental diabetes [10]. Though despite extensive research, the 
precise mechanism for the development and progression of diabetic retinopathy has not 
been determined [11]. The results of several studies have indicated that in this condition 
too, neuronal abnormalities such as retinal ganglion cell death, are associated with the 
pathogenesis of the retinopathy [12-13]. It has shown that neuron and ganglion cells 
undergo hyperglycemia- induced apoptosis in vitro [12], although the mechanism of 
initiation of the apoptotic cascade is unknown. This is important because once RGCs die by 
apoptosis, visual function cannot be recovered because retinal neurons do not regenerate 
[14]. Thus, the focus of research has turned to determining whether neuroprotective 
procedures can protect the function of RGCs and their long axons in diabetic retinas [15]. 
Because diabetes is associated with high levels of glucose in the serum, the biochemical 
effect of neuronal cell death and regeneration under high- glucose (HG) or diabetic 
conditions have been studied [16]. It has been reported that exposure of retinal explants to 
advanced glycation end products can induce neuronal degeneration by caspase-3 activation 
[17]. Another study showed that exposure of neurons to a HG medium can enhance 
intracellular Ca2+ responses that may be responsible for retinal cell death in the early stage 




neurotrophic factors can function as neuroprotective agents [19]. Thus, brain-derived 
neurotrophic factor (BDNF) has been shown to have neuroprotective properties in both 
diabetic and physical injured models [20-21]. Neurotrophin-4 (NT-4) has similar 
neuroprotective effects in the survival and regeneration of RGCs in vitro and in vivo [22]. 
Therefore as evidenced by the literature the key cell type implicated in the development of 
glaucoma and diabetic retinopathy is the retinal ganglion cell (RGC) and apoptosis of RGC 
is one of the mechanisms leading to visual loss [23-24]. A cause of apoptosis is 
excitotoxicity due to excessive synaptic glutamate activity. Glutamate is one of the major 
excitatory neurotransmitter in the brain and exists in high concentrations in the retina. It is 
thought that exposure to moderately elevated levels of glutamate can trigger cellular 
processes in neurons that eventually lead to apoptosis [25]. In addition, increasing evidence 
shows that several neuronal cell types in the retina are highly susceptible to hyperglycemia-
mediated apoptosis [26]. Cell culture models have substantially contributed to the 
characterization of the pathophysiology of retinal neurodegeneration, providing a simplified 
tool to investigate in an isolated context, the detrimental effects of high glucose (HG) 
concentrations and excessive amount of glutamate [27-28]. In recent years, research efforts 
have been made to identify neuroprotective drugs able to prevent visual field loss and 
preserve visual function. Infact, RGC death occurs through a complex series of pathological 
events and involves several pathways. Changes in neurotrophin signaling, oxidative stress, 
excitotoxicity, mitochondrial dysfunction, protein misfolding, hypoxic and ischemic 
phenomena, and autoimmunity, have all been identified as contributing factors to 
glaucoma-associated RGC death [29]. However, the failure of recent clinical trials raised 




[30]. Based on results of the latest investigations, it is reasonable to assert that a single 
constituent that affects one target has limited efficacy in preventing the progression of 
multifactorial diseases. A large body of research revealed that the use of a combination of 
compounds with synergistic multi-target effects may offer a more powerful approach for 
disease prevention, including retinal neurodegeneration [31-35]. This study investigated 
whether co-treatment with more compounds exhibits synergistic neuroprotective effects in 
experimental conditions associated with neuroretinal degeneration such as glutamate-
induced excitotoxicity and HG-induced neurotoxicity. Citicoline (cytidine-5'-
diphosphocholine/citicoline, CDP-choline) is an intermediate in the synthesis of 
phosphatidylcholine, a component of cell membranes. Citicoline is a nontoxic and well-
tolerated drug used in the pharmacology of brain insufficiency and some other neuronal 
disorders. After administration, citicoline is quickly transformed to cytidine and choline, 
and both enter neuronal cells separately. Citicoline is believed to provide neuroprotective 
effect by enhancing phosphatidylcholine synthesis followed by stabilizing the intracellular 
conditions and reducing phospholipase A2 activation [36]. It has been shown that citicoline 
produces neuroprotective effects in a variety of central nervous system (CNS) injury 
models, particularly cerebral ischemia [37]. Though citicoline is prescribed for brain injury, 
Alzheimer's, and Parkinson's disorders in Japan and Europe. In addition, oral and 
intramuscular administration of citicoline significantly improves retinal and cortical 
responses in glaucoma patients [38]. Two clinical studies have shown that systemic 
treatment with citicoline is effective in glaucoma patients independent of the intraocular 
pressure [39-40]. At the experimental level, it has been reported that citicoline is a 




retinopathy. The effects proposed to explain the neuroprotective actions of citicoline have 
been thoroughly reviewed and include anti-apoptotic effects, neurotrophic properties, 
protection after partial optic nerve crush, reduction of excitotoxicity, effects on non-
glutamatergic neurotransmitter systems, and effects on remyelination [41-42]. In recent 
human studies, citicoline appears to be a promising agent to improve cognitive impairment 
[43]. Homotaurine (3-amino -1 propane sulfonic acid, tramiprosate), analogue of 4-
aminobutyrate (γ-aminobutyric acid, GABA), is a small natural aminosulfonate compound 
endowed with neuromodulatory effects. This compound has been identified in different 
species of marine red algae and then chemically synthesized and introduced into clinical 
use under the name of tramiprosate [44]. Wu S et al reported its neuroprotective effect 
following ischemic stroke in rats [45], while the post-hoc analysis of a failed phase III 
clinical trial with tramiprosate demonstrated significant positive effects on secondary 
endpoints in patients with Alzheimer’s [46]. It has been shown that homotaurine may 
interfere with several cellular pathways, both in vitro and in vivo experimental models. It 
was noticed that this substance could manifeste neuroprotective and neurotropic activities 
through different mechanisms including effects against the oxidative damage to DNA, anti-
fibrillogenic activity, anti-nociceptive and analgesic activities. More interestingly, beyond 
its neuroprotective and neurotropic effects related to the activation of GABA type A 
receptors, it has been observed that homotaurine prevents the neurotoxicity of Aβ peptide 
by reducing amyloid aggregation [47]. Considering the distinct chemical properties of 
citicoline and homotaurine, the purpose of this study was to assess whether co-treatment of 





2. Materials and Methods 
 
2.1 Retinal Cultures 
 
The study has been approved by the appropriate ethics committee and have therefore been 
performed in accordance with the ethical standards laid down in the 1964 Declaration of 
Helsinki and its later amendments. Primary cultures were obtained from the retinas of fetal 
Wistar rats (18–19 days’ gestation), following a procedure described elsewhere [48]. 
Briefly, retinal tissues were mechanically dissociated, and the cell suspensions were plated 
60-mm dish (0.8–1.0x10
6
 cells/ml) (Corning, Acton, MA). Retinal cultures were incubated 
in Eagle’s minimal essential medium (MEM) containing 2 mM glutamine, penicillin-
streptomycin (100 U/ml, 50 μg/ml), and 25 mM N-(2-hydroxyethyl) piperadine-N′-(2-
ethanesulfonic acid) (HEPES) under an atmosphere of 5% CO2 in air. The medium was 
supplemented with 10% heat-inactivated fetal bovine serum during the 1st week and with 
10% horse serum for the remaining 8–11 days. To eliminate non-neuronal cells, 10 μM 
cytosine arabinoside (Sigma, St. Louis, MO) was added to the culture. Only those cultures 
maintained for 9–11 days in vitro, and only isolated cells were used in this study. Previous 
studies using cultured rat retinal cells demonstrated that cell viability was reduced by 
exposure to glutamate (1 mM) for 10 min. followed by postincubation in glutamate-free 
medium for more than 1 hour [49, 50]. It was also shown that there was no significant 
difference between the values of reduction in cell viability between 1-hour and 24-hour 
incubations [51]. In the present study glutamate neurotoxicity was assessed using a 25-min 
exposure to 100 μM glutamate followed by a 24-hour incubation in glutamate-free medium. 
In the second series of experiments, the cells were treated with HG concentrations to mimic 




confluent, the culture medium was supplemented with glucose, reaching a final 
concentration of 30 mM. Retinal cells were exposed to HG for 96 hours. The concentration 




2.2 Cell Viability 
 
The assay used to assess cell viability in retinal cells was the (3,4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) reduction assay modified from that of Mosmann 
[52]. To evaluate the effect of citicoline and homotaurine on cell survival, the cells were 
subdivided into three groups and treated for 24 hours with 1 μM, 10 μM, and 100 μM of 
citicoline (Kyowa Hakko Bio Co., Ltd., Tokyo, Japan) and with 1 μM, 10 μM, and 100 μM 
of homotaurine (Truffini e Reggè Farmaceutici, Milan, Italy). To evaluate the 
neuroprotective effects of citicoline and homotaurine, cells were treated with citicoline 100 
μM, homotaurine 100 μM or with citicoline + homotaurine 100 μM, 24 hours before 
glutamate treatment and 30 min. before HG treatment. MTT was added to wells at a final 
concentration of 0.5 mg/mL for 1 hour at 37°C. After this time, the medium was removed 
and reduced MTT (blue formazan product) was solubilized by adding 100 μL dimethyl 
sulfoxide to each well. After agitation of plates for 15 min., the optical density of the 
solubilized formazan product in each well was measured using an automatic microplate 







2.3 Apoptotic Cell Death Detection 
 
Apoptosis was determined by using a Cell Death Detection ELISA
PLUS
 kit (Roche Applied 
Science, Indianapolis, IN). This photometric enzyme immunoassay provides the 
quantitative determination of oligonucleosomes generated from the apoptotic cells. After 
the treatments, cells were washed, harvested, lysed, centrifuged to remove nuclei, and 
supernatants were collected. An aliquot of the supernatant from each sample was incubated 
with immunoreagents in 96-well streptavidin-coated plates on a shaker. After three washes 
with incubation buffer, the substrate solution was added to each well, and absorbance was 
read at 405 nm in a microplate reader. The enrichment of oligonucleosomes released into 
the cytoplasm was calculated as absorbance of sample cells/absorbance of control cells. 
 
 
2.4 Statistical Analysis 
 
Data are expressed as the mean ± standard error of the mean (SEM) of three independent 
experiments. Statistical significance was determined using one-way analysis of variance 










3.1 Viability of Primary Retinal Cultures is not affected by treatment with citicoline 
or homotaurine 
 
To determine the potential neuroprotective activity of citicoline and homotaurine, we firstly 
treated retinal cells with increasing concentrations of citicoline or homotaurine for 24 
hours. We investigated whether 1 μM, 10 μM, and 100 μM of citicoline or homotaurine 
may contribute to a reduced cell viability in retinal cells. As shown in Figure 1, retinal cells 
were well preserved in citicoline- or homotaurine-treated cultures, with no evidence of 
toxicity or significant loss of viability after treatments. Moreover, it has been previously 
shown that 100 μM of citicoline is not harmful for retinal neuroglial cells in vitro and 100 
μM of homotaurine is an effective concentration to enhance neuroprotection in a model of 
experimental glaucoma [53, 54]. Therefore, this concentration of citicoline and 
homotaurine was used for all subsequent experiments. 
 
3.2 Co-treatment of Citicoline and Homotaurine Exerts Synergistic Effects Against 
Excitotoxic Cell Damage 
 
To evaluate whether co-treatment with citicoline and homotaurine was able to induce a 
synergistic neuroprotective effect against glutamate excitotoxicity, retinal cell cultures were 
exposed to citicoline 100 μM, homotaurine 100 μM and citicoline + homotaurine 100 μM, 
24 hours before glutamate treatment. In the presence of 100 μM citicoline, a significant 
increase in cell viability was observed (Figure 2). Although less effective than citicoline in 




treatment with 100 μM homotaurine (Figure 2). These data are consistent with previous 
studies, suggesting the neuroprotective activities of these compounds when used alone [55, 
56]. However, the combination between citicoline and homotaurine significantly increased 
viability of retinal cells after glutamate exposure (Figure 2). These results showed that 
combined administration of citicoline and homotaurine possess a cytoprotective activity 
greater than the response achieved by the single compounds. 
 
3.3 Co-treatment of Citicoline and Homotaurine Reduces Apoptosis Induced by 
Administration of Glutamate and HG 
 
Next, we determined whether the synergistic effect of citicoline and homotaurine is 
associated with cytoprotection against glutamate-induced apoptosis. Apoptosis, measured 
by the number of oligonucleosomes released, was significantly decreased in cells incubated 
only with 100 μM of citicoline 24 hours before glutamate treatment (Figure 3). 
Homotaurine 100 μM also was able to decrease the neurotoxic effect glutamate in terms of 
reduction in apoptotic rate (Figure 3). However, as shown in Figure 3, reduction of retinal 
cells apoptosis induced by these compounds in combination was higher than the groups of 
either citicoline or homotaurine treated alone. These data suggest that citicoline or 
homotaurine in combination synergistically reduce apoptosis in glutamate-treated retinal 
cells. In addition, a neuroprotective effect was also observed against apoptosis induced by 
HG treatment. Primary retinal cell cultures, exposed to HG treatment showed an increase in 
apoptosis, which was reduced in the presence of 100 μM citicoline (Figure 4). Significant 
neuroprotective effects on apoptosis induced by HG treatment were also reported following 
treatment with homotaurine 100 μM (Figure 4). Again in the presence of co-treatment with 




exposed to HG toxicity (Figure 4). Collectively, these results suggested that the enhanced 
reduction of apoptosis by combination treatment with citicoline and homotaurine may be a 









RGC death is the final event leading to visual impairment in glaucoma and diabetic 
retinopathy; therefore, identification of neuroprotective strategies able to slow down or 
prevent the process is one of the main challenges for ophthalmolgy research. The purpose 
of our study was to investigate the neuroprotective potential of a combined treatment with 
two substances, each endowed with different neuroprotective properties. We tested 
synergistic neuroprotective effects of citicoline and homotaurine in combination on primary 
retinal cells exposed to glutamate toxicity and HG levels. The data demonstrated that co-
treatment of citicoline and homotaurine has a direct neuroprotective effect in an 
experimental model of retinal neurodegeneration. Glutamate-induced excitotoxicity is 
implicated in the pathophysiology of several degenerative diseases of the retina, including 
glaucoma [56]. Moreover, HG-induced neurotoxicity is a characteristic of diabetic 
retinopathy [57]. Thus, the results of our study provide a rationale for the use of citicoline 
and homotaurine as potential therapeutic compounds in acute and chronic 
neurodegenerative diseases of the retina. To explain the reported synergic neuroprotection, 
we can speculate that, in our system, the antioxidant properties of homotaurine per se or 
citicoline alone might not be sufficient to protect RGCs, though they might partly buffer the 
burst of oxidative stress that occurs after glutamate and HG concentration exposure. The 
association of both compounds might in turn generate a more permissive environment for 
the neuroprotective effects exerted by each substance. One hypothesis that may be 
considered is that, the presence of homotaurine and citicoline toghether increases the 




upregulated as part of the retinal defense responses. To our knowledge, this is the first 
report demonstrating that the neurotoxic effect of glutamate and HG is greatly reduced by 
simultaneous application of citicoline and homotaurine. Therefore, the neuroprotective 
activity observed here provides also evidence that combination treatment with these 
compounds may be a promising strategy to support retinal health. Indeed, an emerging 
therapeutic approach to counteract neuronal vulnerability associated with aging involves 
the mixture of distinct compounds, in order to improve the neuroprotective efficacy and 
pharmacokinetic–pharmacodynamic properties [58-59]. Although the neuroprotective 
mechanisms of citicoline have been shown in various experimental models of retinal 
degeneration [60], the presence of homotaurine may increase the neuroprotective effects 
exerted by this compound. Moreover, it should be highlighted that recent studies have 
associated the neuroprotective activity of citicoline to its ability in activating sirtuin-1 
(SIRT1), a member of the mammalian sirtuins important for neuronal plasticity, cognitive 
functions, as well as protection against aging-associated neuronal degeneration and 
cognitive decline [42, 43]. The clinical efficacy of homotaurine has been extensively 
studied in several randomized, double-blind, placebo controlled Phase I, II and III clinical 
trials, showing significant positive effects on secondary endpoints in patients with 
Alzheimer’s disease [61, 62]. More interestingly, the association of homotaurine, carnosine, 
and forskolin (Coleus forskohlii root extract) has shown synergistic neuroprotective effects 
on RGC both in vitro and in vivo in a mouse model of hypertensive retinal ischemia [49, 
63]. Although more than one mechanism might account these synergistic properties, this 
neuroprotection was associated with reduced calpain activity, upregulation of 




kinase-3β (GSK-3β). Moreover, a recent pilot study demonstrated that oral administration 
of homotaurine, forskolin, carnosine, and folic acid improves intraocular pressure in 
patients with primary open angle glaucoma [64]. Therefore, a multitarget approach by using 
a combination of molecules may be a more promising strategy to prevent retinal 
degeneration or slow down glaucomatous progression. In several experimental models of 
glaucoma, abundant evidence has been provided that RGC apoptosis is the earliest form of 
cell loss of the disease [65-66]. Our results show that, following exposure to toxic levels of 
glutamate and glucose, co-treatment of citicoline and homotaurine reduced apoptosis of 
primary retinal cells (Figure 3, Figure 4). Although the neuroprotective mechanism of 
action of citicoline and homotaurine is not clear at this time, other authors have observed 
that particularly citicoline may reduce the retinal neuronal apoptosis induced by HG, 
increasing the expression of endogenous trophic factors such as brain-derived neurotrophic 
factor (BDNF) and ciliary neurotrophic factor (CNTF), that are transiently upregulated as 
part of the retinal defense responses. In addition, these effects were associated with the 
reduction of the expression of active forms of caspases-9 and -3 [67-68]. Alternatively, 
considering that toxic levels of glutamate and glucose induce an oxidative stress, by 
increasing reactive oxygen species (ROS), our findings may be also correlated with 
citicoline and homotaurine antioxidant activities [69-70]. It should be also mentioned that 
taurine (2-aminoethanesulfonate), homotaurine analogue and one of the most abundant free 
amino acids in the brain, has been shown to attenuate retinal glial apoptosis in diabetic rats, 
suggesting an anti-apoptotic action. It has also been suggested that taurine prevents 
glutamate excitotoxicity by increasing glutamate transporter expression, thereby decreasing 




glaucomatous optic neuropathy, since RGCs are highly dependent on taurine for survival 
[71-74]. Altogether, the data presented here strongly suggest that citicoline and 
homotaurine in combination could be a potential new strategy for the prevention and 









In conclusion, the present study demonstrated that co-treatment of citicoline and 
homotaurine exhibited synergistic neuroprotective effects on well-known experimental 
conditions of retinal neurodegeneration. We showed that a combined treatment can afford 
neuroprotection in retinal ischemia models. Citicoline and homotaurine promoted the 
survival and viability of retinal cells cultures incubated in glutamate and HG media. The 
neuroprotective effect of these factors are correlated with the preservation and the reduction 
on neuronal apoptosis in primary retinal cells. Further studies are needed to clarify the 
mechanisms responsible for the observed neuroprotective properties, although our data 
suggest a reduction of apoptosis. Finally, these findings also suggest that co-treatment of 
citicoline and homotaurine may represent an interesting strategy to achieve neuroprotection 
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Figure 1: Effects of citicoline and homotaurine on cell viability. MTT assay shows that 
retinal cells were well preserved in citicoline- or homotaurine-treated cultures, with no 
evidence of toxicity after treatment at 1, 10 or 100 µM. All data are represented as the mean 























































Figure 2: Co-treatment of citicoline and homotaurine protects retinal cells against 
glutamate-induced cytotoxicity. MTT assay was performed to detect cell viability after 
treatment with CitC and Hot against glutamate-induced cytotoxicity in retinal cells. The 
combined administration of citcoline and homotaurine demonstrated a significant 
synergistic cytoprotective effect. The results represent the mean ± SEM of three 
independent experiments. ANOVA followed by Tukey’s post hoc test was carried out to 
determine the level of significance., p < 0.001 vs glutamate. , p < 0.001 vs Citicoline and 








































Figure 3: Co-treatment of citicoline and homotaurine significantly reduces the apoptotic 
rate in glutamate-treated cells. A cell death detection ELISA kit was used to determine 
cytoplasmic DNA oligonucleosome fragments associated with apoptotic cell death. The 
enrichment of oligonucleosomes released into the cytoplasm was calculated as absorbance 
of sample cells/absorbance of control cells. The administration of citicoline plus 
homotaurine demonstrated a synergistic effect in terms of apoptosis reduction. The results 
represent the mean ± SEM of three independent experiments. ANOVA followed by 
Tukey’s post hoc test was carried out to determine the level of significance. #, p < 0.001 vs 
glutamate. ##, p < 0.001 vs citicoline and homotaurine alone. Abbreviations: Citicoline 


















































Figure 4: Combined administration of citicoline and homotaurine significantly reduces the 
apoptotic rate in high glucose-treated cells. Oligonucleosome fragments associated with 
apoptosis were quantified by cell death detection ELISA. As compared to the untreated 
cells, the administration of citicoline plus homotaurine demonstrated a statistically 




independent experiments are expressed as mean ± SEM of the absorbance from treated 
cells relative to absorbance of untreated cells. Comparison between data sets was 
performed using ANOVA followed by Tukey’s post hoc test, p < 0.001 vs high glucose 96 
hours. , p < 0.001 vs Citicoline and homotaurine alone. Abbreviations: Citicoline (CitC); 
homotaurine (Hot); high glucose (HG). 
